Revvity PE Ratio 2010-2024 | RVTY
Current and historical p/e ratio for Revvity (RVTY) from 2010 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Revvity PE ratio as of November 05, 2024 is 26.63.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Revvity PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2024-11-05 | 125.96 | 104.10 | |
| 2024-03-31 | 104.80 | $1.21 | 86.61 |
| 2023-12-31 | 109.03 | $5.50 | 19.82 |
| 2023-09-30 | 110.34 | $5.95 | 18.54 |
| 2023-06-30 | 118.33 | $6.32 | 18.72 |
| 2023-03-31 | 132.68 | $6.71 | 19.77 |
| 2022-12-31 | 139.54 | $3.63 | 38.44 |
| 2024-06-30 | 104.73 | $3.94 | 26.58 |
| 2022-09-30 | 119.68 | $4.90 | 24.42 |
| 2022-06-30 | 141.38 | $5.34 | 26.48 |
| 2022-03-31 | 173.35 | $7.30 | 23.75 |
| 2021-12-31 | 199.71 | $7.47 | 26.73 |
| 2021-09-30 | 172.05 | $7.29 | 23.60 |
| 2020-12-31 | 142.27 | $6.48 | 21.96 |
| 2020-09-30 | 124.36 | $3.68 | 33.79 |
| 2020-06-30 | 97.13 | $4.30 | 22.59 |
| 2020-03-31 | 74.48 | $3.59 | 20.75 |
| 2019-12-31 | 96.00 | $3.91 | 24.55 |
| 2021-06-30 | 153.24 | $3.65 | 41.98 |
| 2019-09-30 | 84.14 | $2.10 | 40.07 |
| 2019-06-30 | 95.10 | $2.27 | 41.90 |
| 2019-03-31 | 95.05 | $2.22 | 42.82 |
| 2018-12-31 | 77.42 | $2.13 | 36.35 |
| 2018-09-30 | 95.79 | $1.12 | 85.53 |
| 2018-06-30 | 72.05 | $1.25 | 57.64 |
| 2018-03-31 | 74.43 | $2.52 | 29.54 |
| 2017-12-31 | 71.81 | $2.64 | 27.20 |
| 2017-09-30 | 67.67 | $3.60 | 18.80 |
| 2017-06-30 | 66.79 | $3.31 | 20.18 |
| 2017-03-31 | 56.84 | $2.05 | 27.73 |
| 2016-12-31 | 50.99 | $2.13 | 23.94 |
| 2016-09-30 | 54.79 | $2.15 | 25.48 |
| 2016-06-30 | 51.12 | $2.10 | 24.34 |
| 2016-03-31 | 48.17 | $1.95 | 24.70 |
| 2015-12-31 | 52.09 | $1.88 | 27.71 |
| 2015-09-30 | 44.62 | $1.54 | 28.98 |
| 2015-06-30 | 51.04 | $1.43 | 35.69 |
| 2015-03-31 | 49.52 | $1.44 | 34.39 |
| 2014-12-31 | 42.28 | $1.65 | 25.62 |
| 2014-09-30 | 42.08 | $1.74 | 24.18 |
| 2014-06-30 | 45.13 | $1.62 | 27.86 |
| 2013-12-31 | 39.60 | $1.46 | 27.12 |
| 2013-09-30 | 36.19 | $0.75 | 48.25 |
| 2013-06-30 | 31.09 | $0.65 | 47.83 |
| 2013-03-31 | 32.12 | $0.69 | 46.55 |
| 2012-12-31 | 30.24 | $0.61 | 49.57 |
| 2012-09-30 | 28.01 | $-0.00 | 0.00 |
| 2012-06-30 | 24.46 | $0.05 | 489.12 |
| 2012-03-31 | 26.15 | $0.01 | 2615.03 |
| 2011-12-31 | 18.85 | $2.27 | 8.30 |
| 2011-09-30 | 18.04 | $3.13 | 5.76 |
| 2011-06-30 | 25.20 | $3.31 | 7.61 |
| 2010-12-31 | 24.05 | $3.27 | 7.36 |
| 2010-09-30 | 21.49 | $1.15 | 18.69 |
| 2010-06-30 | 19.13 | $1.24 | 15.42 |
| 2010-03-31 | 22.05 | $0.87 | 25.34 |
| 2009-12-31 | 18.93 | $0.84 | 22.54 |
| 2011-03-31 | 24.54 | $0.59 | 41.59 |
| 2009-09-30 | 17.63 | $3.76 | 4.69 |
| 2009-06-30 | 15.88 | $3.94 | 4.03 |
| 2009-03-31 | 11.60 | $3.76 | 3.08 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $15.535B | $2.751B |
| Revvity Inc. provides products, services and solutions to the diagnostics, life sciences and applied services markets worldwide. Its operating segment includes Discovery & Analytical Solutions and Diagnostics. Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection and imaging technologies. Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection and imaging technologies. Revvity Inc., formerly known as PerkinElmer Inc., is based in Waltham, Massachusetts. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $96.890B | 12.02 |
| Cencora (COR) | United States | $46.107B | 17.62 |
| DiDi Global (DIDIY) | China | $23.233B | 0.00 |
| ICON (ICLR) | Ireland | $18.679B | 16.64 |
| Avantor (AVTR) | United States | $15.498B | 23.24 |
| Natera (NTRA) | United States | $15.385B | 0.00 |
| Viatris (VTRS) | United States | $13.858B | 4.22 |
| BioMerieux (BMXMF) | France | $13.601B | 0.00 |
| Solventum (SOLV) | United States | $12.636B | 0.00 |
| CochLear (CHEOY) | Australia | $12.565B | 0.00 |
| Medpace Holdings (MEDP) | United States | $10.202B | 28.74 |
| Charles River Laboratories (CRL) | United States | $9.742B | 18.41 |
| Sonic Healthcare (SKHHY) | Australia | $8.273B | 0.00 |
| HealthEquity (HQY) | United States | $7.792B | 42.29 |
| Doximity (DOCS) | United States | $7.787B | 49.34 |
| Bausch + Lomb (BLCO) | Canada | $6.975B | 32.47 |
| Life Times (LTH) | United States | $4.762B | 31.52 |
| PACS (PACS) | United States | $4.502B | 0.00 |
| Sotera Health (SHC) | United States | $4.367B | 23.36 |
| Organon (OGN) | United States | $4.239B | 4.28 |
| Surgery Partners (SGRY) | United States | $3.778B | 41.86 |
| BrightSpring Health Services (BTSG) | United States | $3.070B | 65.30 |
| Ardent Health Partners (ARDT) | United States | $2.577B | 0.00 |
| Alignment Healthcare (ALHC) | United States | $2.546B | 0.00 |
| Concentras Parent (CON) | United States | $2.480B | 0.00 |
| Premier (PINC) | United States | $2.271B | 11.34 |
| GoodRx Holdings (GDRX) | United States | $2.254B | 84.86 |
| GeneDx Holdings (WGS) | United States | $2.057B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $2.036B | 0.00 |
| Teladoc Health (TDOC) | United States | $1.575B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $1.507B | 7.57 |
| Progyny (PGNY) | United States | $1.425B | 25.06 |
| Establishment Labs Holdings (ESTA) | $1.338B | 0.00 | |
| Pediatrix Medical (MD) | United States | $1.319B | 12.91 |
| CareDx (CDNA) | United States | $1.228B | 0.00 |
| Agilon Health (AGL) | United States | $1.123B | 0.00 |
| Embecta (EMBC) | United States | $0.864B | 5.76 |
| InnovAge Holding (INNV) | United States | $0.822B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.790B | 20.69 |
| SBC Medicals (SBC) | United States | $0.722B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.488B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.483B | 0.00 |
| Enhabit (EHAB) | United States | $0.382B | 33.04 |
| DocGo (DCGO) | United States | $0.355B | 13.35 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.309B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.255B | 0.00 |
| ModivCare (MODV) | United States | $0.232B | 7.37 |
| Beauty Health (SKIN) | United States | $0.211B | 0.00 |
| Biodesix (BDSX) | United States | $0.195B | 0.00 |
| LifeMD (LFMD) | United States | $0.192B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.178B | 0.00 |
| MultiPlan (MPLN) | United States | $0.136B | 0.00 |
| Nutex Health (NUTX) | United States | $0.127B | 0.00 |
| So-Young (SY) | China | $0.092B | 22.35 |
| Harvard Apparatus Regenerative Technology (HRGN) | United States | $0.059B | 0.00 |
| Singular Genomics Systems (OMIC) | United States | $0.057B | 0.00 |
| OncoCyte (OCX) | United States | $0.049B | 0.00 |
| NeueHealth (NEUE) | United States | $0.041B | 1.63 |
| Co-Diagnostics (CODX) | United States | $0.039B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.036B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.027B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.027B | 0.00 |
| Oncology Institute (TOI) | United States | $0.021B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.012B | 0.00 |
| XWELL (XWEL) | United States | $0.009B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.007B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.007B | 0.00 | |
| KindlyMD (KDLY) | United States | $0.005B | 0.00 |
| ISpecimen (ISPC) | United States | $0.004B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.003B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.001B | 0.00 |